Maruho Report 20232510,94020182019202020216,9373,5312,68420222023Initiatives in the fiscal year ended September 2023Key theme of strategyAccumulation of API manufacturing know-how and expansion of functionsCompletion of flexible production system and functionsHonest and open activities to ensure reliabilityMain results• Systematically implemented work to increase the production capacity of APIs at Roman Industries Co., Ltd.• Involved in the manufacturing process of outsourcing partners. Promoted consideration of diversification for a stable supply of APIs and raw materials for existing products• Completed the renewal of the filling and packaging building at the Hikone Plant, and introduced new equipment that can accommodate a variety of container sizes and formats• Established a system and mechanism enabling easy identification and mutual searches for spare parts management at the four plants• Completed GS1 barcode reposition and 2D code addition to improve customer satisfaction• Provided tactile labels for reasonable accommodation of patients with skin diseases• Issued new procedures for market research and provision of analytical reagents, and conducted training companywide on the Personal Information Protection Act• Disclosed the number of adverse effects to medical professionals on our website• Continued high-level reliability assurance activitiesCapital expenditure3. Strategy for Value Creation Progress of the Medium-Term PlanProduction and Reliability AssuranceImplementing a production strategy based on product characteristics and fostering an even greater culture of reliability assuranceMaruho has established a production system consisting of four plants: the main Hikone Plant, Nagahama Plant, Tateyama Pharmaceutical Factory Co., Ltd., and Roman Industries Co., Ltd. We offer a stable supply of high-quality pharmaceuticals with one of the highest production capacities of topical formulations in Japan, and we are actively investing management resources to strengthen our bases and systems. We are also focusing on improving the containers and packaging of our products to increase usability and reduce environmental impacts.We are committed to improving reliability assurance. We ensure an honest and open regulatory process from development to application for approval, as well as a reliable supply of products post approval. In addition to preventing quality risks, including in our processes, we guarantee reliability in all of our business activities, including production, and aim to continue contributing to patients through the supply of products and the provision of relevant information.(Millions of yen)6,9376,706
元のページ ../index.html#26